BPTH: Bio-Path Holdings Inc. Stocks News on November 23, 2024

BPTH

GuruFocus.com

2 days ago

Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ...

BPTH

Associated Press Finance

8 days ago

Bio-Path: Q3 Earnings Snapshot

Bio-Path Holdings Reports Third Quarter 2024 Financial Results

BPTH

GlobeNewswire

8 days ago

Bio-Path Holdings Reports Third Quarter 2024 Financial Results

Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024

BPTH

GlobeNewswire

15 days ago

Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024

BPTH

MT Newswires

a month ago

Bio-Path Closes $4 Million Private Equity Offering

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BPTH

GlobeNewswire

a month ago

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BPTH

GuruFocus.com

a month ago

Bio-Path Holdings Inc (BPTH) Q2 2024 Earnings Call Highlights: Financial Improvements and ...

BPTH

MT Newswires

a month ago

Bio-Path Launches $4 Million Private Placement of Shares, Warrants; Shares Fall

BPTH

ACCESSWIRE

a month ago

ACHR, BPTH, PLUG, REGRF:

Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer

BPTH

Benzinga

a month ago

Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer

Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity

BPTH

GlobeNewswire

a month ago

Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity

Bio-Path Holdings Announces Publication in Biomedicines

BPTH

GlobeNewswire

2 months ago

Bio-Path Holdings Announces Publication in Biomedicines

BPTH

Newsfile

3 months ago

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24

Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference

BPTH

GlobeNewswire

3 months ago

Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference

BPTH

MT Newswires

3 months ago

Bio-Path Holdings Reports Tumor Regression in Early Trial for Solid Tumors; Shares Jump Pre-Bell

Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors

BPTH

GlobeNewswire

3 months ago

Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors

BPTH

Associated Press Finance

3 months ago

Bio-Path: Q2 Earnings Snapshot

Bio-Path Holdings Reports Second Quarter 2024 Financial Results

BPTH

GlobeNewswire

3 months ago

Bio-Path Holdings Reports Second Quarter 2024 Financial Results

Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024

BPTH

GlobeNewswire

3 months ago

Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024

Bio-Path Holdings Provides Clinical Update and Expansion Plans

BPTH

GlobeNewswire

4 months ago

Bio-Path Holdings Provides Clinical Update and Expansion Plans

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress

BPTH

GlobeNewswire

5 months ago

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress

BPTH

GlobeNewswire

6 months ago

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BPTH

Newsfile

6 months ago

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24

Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BPTH

GlobeNewswire

6 months ago

Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting

BPTH

GlobeNewswire

6 months ago

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting

Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress

BPTH

GlobeNewswire

6 months ago

Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress

Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting

BPTH

GlobeNewswire

6 months ago

Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting

BPTH

GuruFocus.com

6 months ago

Bio-Path Holdings Inc (BPTH) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...

BPTH

Thomson Reuters StreetEvents

6 months ago

Q1 2024 Bio Path Holdings Inc Earnings Call

BPTH

Associated Press Finance

6 months ago

Bio-Path: Q1 Earnings Snapshot

Bio-Path Holdings Reports First Quarter 2024 Financial Results

BPTH

GlobeNewswire

6 months ago

Bio-Path Holdings Reports First Quarter 2024 Financial Results

Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024

BPTH

GlobeNewswire

6 months ago

Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024

Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BPTH

GlobeNewswire

7 months ago

Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BPTH

Zacks

7 months ago

Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study

Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BPTH

GlobeNewswire

7 months ago

Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

$Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients$

BPTH

GlobeNewswire

7 months ago

Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Bio-Path Holdings Expands Global Patent Portfolio

BPTH

GlobeNewswire

7 months ago

Bio-Path Holdings Expands Global Patent Portfolio

Bio-Path Holdings Provides 2024 Clinical and Operational Update

BPTH

GlobeNewswire

8 months ago

Bio-Path Holdings Provides 2024 Clinical and Operational Update

BPTH

Newsfile

8 months ago

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23

BPTH

Insider Monkey

8 months ago

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript

BPTH

Thomson Reuters StreetEvents

8 months ago

Q4 2023 Bio Path Holdings Inc Earnings Call

Bio-Path Holdings Reports Full Year 2023 Financial Results

BPTH

GlobeNewswire

9 months ago

Bio-Path Holdings Reports Full Year 2023 Financial Results

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024

BPTH

GlobeNewswire

9 months ago

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

BPTH

GlobeNewswire

9 months ago

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

BPTH

Simply Wall St.

9 months ago

When Can We Expect A Profit From Bio-Path Holdings, Inc. (NASDAQ:BPTH)?

EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic

BPTH

Benzinga

10 months ago

EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic

Regis Corporation Reports Continued Profitability for the Second Fiscal Quarter 2024

BPTH

Business Wire

10 months ago

Regis Corporation Reports Continued Profitability for the Second Fiscal Quarter 2024

BPTH

Business Wire

10 months ago

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office

Vicarious Surgical Strengthens Executive Team with Appointment of Randy Clark as Company President

BPTH

Business Wire

10 months ago

Vicarious Surgical Strengthens Executive Team with Appointment of Randy Clark as Company President

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

BPTH

GlobeNewswire

10 months ago

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

15 Cash-Rich Penny Stocks Hedge Funds Are Buying

BPTH

Insider Monkey

10 months ago

15 Cash-Rich Penny Stocks Hedge Funds Are Buying

Agri Supply Chooses Bridgeline’s AI-Powered Smart Search

BPTH

GlobeNewswire

10 months ago

Agri Supply Chooses Bridgeline’s AI-Powered Smart Search

Top Building Materials Retailer Contracts Bridgeline for AI-Powered SmartSearch

BPTH

GlobeNewswire

10 months ago

Top Building Materials Retailer Contracts Bridgeline for AI-Powered SmartSearch

When Will Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Become Profitable?

BPTH

Simply Wall St.

10 months ago

When Will Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Become Profitable?

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

BPTH

GlobeNewswire

10 months ago

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

PodcastOne (Nasdaq: PODC) Renews Agreement With Award Winning Our Fake History Podcast

BPTH

NewMediaWire

10 months ago

PodcastOne (Nasdaq: PODC) Renews Agreement With Award Winning Our Fake History Podcast

Trusted Choice Selects Bridgeline’s WooRank SEO Index

BPTH

GlobeNewswire

10 months ago

Trusted Choice Selects Bridgeline’s WooRank SEO Index

BPTH

Zacks Small Cap Research

10 months ago

CTSO: CytoSorbents reports update on data results from important U.S. and Canadian STAR-T pivotal trial.

Nukkleus Signs MOU to Substantially Increase Holdings in Jacobi Asset Management

BPTH

Business Wire

10 months ago

Nukkleus Signs MOU to Substantially Increase Holdings in Jacobi Asset Management

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

BPTH

GlobeNewswire

10 months ago

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

Altisource Asset Management Corporation Repurchases Preferred Shares in Global Settlement With Luxor Capital

BPTH

Business Wire

10 months ago

Altisource Asset Management Corporation Repurchases Preferred Shares in Global Settlement With Luxor Capital

Sotherly Hotels Inc. Schedules Fourth Quarter 2023 Earnings Release and Conference Call

BPTH

GlobeNewswire

10 months ago

Sotherly Hotels Inc. Schedules Fourth Quarter 2023 Earnings Release and Conference Call

ReWalk Robotics Ltd. to Present at Sidoti Virtual Investor Conference on January 17

BPTH

GlobeNewswire

10 months ago

ReWalk Robotics Ltd. to Present at Sidoti Virtual Investor Conference on January 17

Ekso Bionics Announces $4.6 Million Registered Direct Offering

BPTH

GlobeNewswire

10 months ago

Ekso Bionics Announces $4.6 Million Registered Direct Offering

$Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients$

BPTH

GlobeNewswire

10 months ago

Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients

Hycroft Delivers More High-Grade - Expands New Silver System at Brimstone

BPTH

PR Newswire

10 months ago

Hycroft Delivers More High-Grade - Expands New Silver System at Brimstone

Ekso Bionics Launches GaitCoach Software for EksoNR

BPTH

GlobeNewswire

10 months ago

Ekso Bionics Launches GaitCoach Software for EksoNR

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

BPTH

GlobeNewswire

10 months ago

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

First ReWalk Personal Exoskeleton Claim Paid by Medicare

BPTH

GlobeNewswire

a year ago

First ReWalk Personal Exoskeleton Claim Paid by Medicare

Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results

BPTH

GlobeNewswire

a year ago

Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results

Oncternal Therapeutics Announces Reverse Stock Split

BPTH

GlobeNewswire

a year ago

Oncternal Therapeutics Announces Reverse Stock Split

ReWalk Robotics CEO Issues Year-End 2023 Open Letter to Shareholders and Provides 2024 Commercial and Operational Priorities

BPTH

GlobeNewswire

a year ago

ReWalk Robotics CEO Issues Year-End 2023 Open Letter to Shareholders and Provides 2024 Commercial and Operational Priorities

Fenbo Holdings Limited Announces Appointment of Mr. Meng Derong as Co-Chairman and Independent Non-Executive Director

BPTH

GlobeNewswire

a year ago

Fenbo Holdings Limited Announces Appointment of Mr. Meng Derong as Co-Chairman and Independent Non-Executive Director

Nukkleus Releases Updated Corporate Presentation: Lays Out Vision for Building Financial Infrastructure of the Future

BPTH

PR Newswire

a year ago

Nukkleus Releases Updated Corporate Presentation: Lays Out Vision for Building Financial Infrastructure of the Future

Stronghold Announces Addition of up to ~1 EH/s Through Bitcoin Miner Purchases and an Option to Purchase Bitcoin Miners

BPTH

GlobeNewswire

a year ago

Stronghold Announces Addition of up to ~1 EH/s Through Bitcoin Miner Purchases and an Option to Purchase Bitcoin Miners

BTC Digital Ltd. Announces Purchase of 2,000 Units of T21 Miners

BPTH

PR Newswire

a year ago

BTC Digital Ltd. Announces Purchase of 2,000 Units of T21 Miners

Stronghold Digital Mining Inc CEO Gregory Beard Sells 38,759 Shares

BPTH

GuruFocus.com

a year ago

Stronghold Digital Mining Inc CEO Gregory Beard Sells 38,759 Shares

Estimating The Fair Value Of Nukkleus Inc. (NASDAQ:NUKK)

BPTH

Simply Wall St.

a year ago

Estimating The Fair Value Of Nukkleus Inc. (NASDAQ:NUKK)

Foremost Lithium Announces a 7,500 Metre Winter Drill Program on Its Zoro Lithium Property

BPTH

GlobeNewswire

a year ago

Foremost Lithium Announces a 7,500 Metre Winter Drill Program on Its Zoro Lithium Property

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

BPTH

GlobeNewswire

a year ago

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

BPTH

Business Wire

a year ago

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

ASHFORD TRUST SETS FOURTH QUARTER EARNINGS RELEASE AND CONFERENCE CALL DATES

BPTH

PR Newswire

a year ago

ASHFORD TRUST SETS FOURTH QUARTER EARNINGS RELEASE AND CONFERENCE CALL DATES

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

BPTH

GlobeNewswire

a year ago

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

Fujian Blue Hat Interactive Entertainment Technology First Half 2023 Earnings: US$0.36 loss per share (vs US$1.02 loss in 1H 2022)

BPTH

Simply Wall St.

a year ago

Fujian Blue Hat Interactive Entertainment Technology First Half 2023 Earnings: US$0.36 loss per share (vs US$1.02 loss in 1H 2022)

$Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma$